0000731766-23-000026.txt : 20230414 0000731766-23-000026.hdr.sgml : 20230414 20230414060256 ACCESSION NUMBER: 0000731766-23-000026 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 17 CONFORMED PERIOD OF REPORT: 20230414 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20230414 DATE AS OF CHANGE: 20230414 FILER: COMPANY DATA: COMPANY CONFORMED NAME: UNITEDHEALTH GROUP INC CENTRAL INDEX KEY: 0000731766 STANDARD INDUSTRIAL CLASSIFICATION: HOSPITAL & MEDICAL SERVICE PLANS [6324] IRS NUMBER: 411321939 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-10864 FILM NUMBER: 23819610 BUSINESS ADDRESS: STREET 1: UNITEDHEALTH GROUP CENTER STREET 2: 9900 BREN ROAD EAST CITY: MINNEAPOLIS STATE: MN ZIP: 55343 BUSINESS PHONE: 9529361300 MAIL ADDRESS: STREET 1: 9900 BREN ROAD EAST CITY: MINNETONKA STATE: MN ZIP: 55343 FORMER COMPANY: FORMER CONFORMED NAME: UNITED HEALTHCARE CORP/ DATE OF NAME CHANGE: 20000309 FORMER COMPANY: FORMER CONFORMED NAME: UNITED HEALTHCARE CORP DATE OF NAME CHANGE: 19920703 8-K 1 unh-20230414.htm 8-K unh-20230414
0000731766false00007317662023-04-142023-04-14

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
—————————————
FORM 8-K
—————————————
Current Report
Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934
Date of report (Date of earliest event reported): April 14, 2023
—————————————
UNITEDHEALTH GROUP INCORPORATED
(Exact name of registrant as specified in its charter)
—————————————
Delaware1-1086441-1321939
(State or other jurisdiction of incorporation)
(Commission File Number)
(I.R.S. Employer Identification No.)
UnitedHealth Group Center, 9900 Bren Road East,Minnetonka,Minnesota55343
(Address of principal executive offices)(Zip Code)
Registrant’s telephone number, including area code: (952) 936-1300
N/A
(Former name or former address, if changed since last report.)
—————————————
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered
Common Stock, $.01 par valueUNHNew York Stock Exchange
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.



Item 2.02.    Results of Operations and Financial Condition.

On April 14, 2023, UnitedHealth Group Incorporated (the “Company”) issued a press release announcing its first quarter 2023 results. A copy of the press release is furnished herewith as Exhibit 99.1 and incorporated herein by reference.

The information in this Item 2.02 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, nor shall it be deemed incorporated by reference in any Company filing under the Securities Act of 1933 or the Securities Exchange Act of 1934, except as shall be expressly set forth by specific reference in such filing.
Item 9.01.    Financial Statements and Exhibits.
ExhibitDescription
104Cover Page Interactive Data File (formatted as Inline XBRL).



SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: April 14, 2023                 
UNITEDHEALTH GROUP INCORPORATED
By: /s/ Kuai H. Leong
Kuai H. Leong
Deputy Corporate Secretary

EX-99.1 2 a2023q1exhibit991.htm EX-99.1 Document

uhglogoa.jpg
UnitedHealth Group Reports First Quarter 2023 Results
Revenues of $91.9 Billion, Grew 15% Year-Over-Year
Earnings from Operations Grew 16%
Cash Flows from Operations were $16.3 Billion; Adjusted Cash Flows from Operations were $5.1 Billion
Earnings were $5.95 Per Share, Adjusted Earnings $6.26 Per Share
MINNETONKA, Minn. (April 14, 2023) – UnitedHealth Group (NYSE: UNH) reported first quarter 2023 results reflecting consistent broad-based growth at Optum and UnitedHealthcare.

“Our strong, enterprise-wide growth this quarter is a direct result of our colleagues’ unwavering commitment to offering more health services to more people and connecting consumers with greater access to high-quality, affordable care,” said Andrew Witty, chief executive officer of UnitedHealth Group.

Growth in the first quarter was led by serving more people across the enterprise and the company’s expanding capabilities to care for them more comprehensively. The company increased its full year net earnings outlook to $23.25 to $23.75 per share and adjusted net earnings to $24.50 to $25.00 per share.
Page 1 of 6




uhglogoa.jpg
Quarterly Financial Performance
Three Months Ended
March 31,March 31,December 31,
202320222022
Revenues$91.9 billion$80.1 billion$82.8 billion
Earnings from Operations$8.1 billion$7.0 billion$6.9 billion
Net Margin6.1%6.3%5.8%
UnitedHealth Group’s first quarter 2023 revenues grew 15% to $91.9 billion year-over-year, including diversified double-digit growth at both Optum and UnitedHealthcare.
First quarter 2023 earnings from operations were $8.1 billion, an increase of 16%, with strong contributions from both Optum and UnitedHealthcare. Year-over-year earnings growth was led by Optum Health as a result of its growing positive impact in serving patients with value-based care services.
The first quarter 2023 medical care ratio at 82.2% compared to 82% last year, due to business mix. Days claims payable were 47.8, compared to 49.9 in the fourth quarter 2022 and 49.1 in the first quarter 2022. Favorable medical reserve development in the first quarter of $470 million compared to $620 million in the fourth quarter 2022 and $290 million in the year ago first quarter.
The first quarter 2023 operating cost ratio of 14.8% increased from 14.2% in 2022 due to business mix and the company’s continued investments to accelerate and support future growth opportunities, partially offset by continued productivity advances.
Cash flows from operations for the first quarter 2023 were $16.3 billion or 2.8-times net income. Excluding the impact of April CMS payments received at the end of March, adjusted cash flows from operations were $5.1 billion or 0.9-times net income, consistent with the company’s outlook. The company returned $3.5 billion to shareholders in the first quarter through dividends and share repurchases. Return on equity of 28.2% in the quarter reflected the company’s consistent and diverse earnings profile and efficient capital structure.
Page 2 of 6



uhclogowithra.jpg
UnitedHealthcare provides health care benefits globally, serving individuals and employers, and Medicare and Medicaid beneficiaries. UnitedHealthcare is dedicated to improving the value customers and consumers receive by improving health and wellness, enhancing the quality of care received, simplifying the health care experience and reducing the total cost of care.
Quarterly Financial Performance
Three Months Ended
March 31,March 31,December 31,
202320222022
Revenues$70.5 billion$62.6 billion$63.0 billion
Earnings from Operations$4.3 billion$3.8 billion$2.9 billion
Operating Margin6.2%6.1%4.7%
UnitedHealthcare first quarter revenues grew 13% to $70.5 billion and operating earnings grew 14% to $4.3 billion, reflecting growth in the number of people served.
In the first quarter of 2023, UnitedHealthcare grew to serve nearly 2 million more people than a year ago, with broad-based growth across the company’s commercial, community-based and senior benefit offerings. The number of consumers served with domestic commercial benefit offerings grew 665,000 in the first quarter 2023 compared to year-end 2022, reflecting continued focus on innovative, affordable, consumer-centric benefit plans. Recent Medicaid contract awards in Indiana and Texas will expand the products and geographies served. UnitedHealthcare is pacing strongly to its outlook for another year of market-leading growth in serving more people through its Medicare Advantage offerings.
Page 3 of 6




optumlogoforearningsreleasea.jpg
Optum’s health services businesses serve the global health care marketplace, including payers, care providers, employers, governments, life sciences companies and consumers. Using market-leading information, analytics and technology to yield clinical insights, Optum helps improve overall health system performance: optimizing care quality, reducing care costs and improving the consumer experience.
Quarterly Financial Performance
Three Months Ended
March 31,March 31,December 31,
202320222022
Revenues$54.1 billion$43.3 billion$47.9 billion
Earnings from Operations$3.7 billion$3.2 billion$4.0 billion
Operating Margin6.9%7.3%8.3%
Optum first quarter revenues grew 25% to $54.1 billion and operating earnings grew 19% to $3.7 billion.
Optum Health revenue per consumer served increased 34% over the year ago quarter, driven by growth in people served under value-based care arrangements. The results reflect continued expansion of the care services offered to meet patients’ care needs across at-home, digital and in-clinic settings.
Optum Insight’s revenue backlog increased by 35% to $30.7 billion, compared to a year ago, driven by the addition of Change Healthcare and growth in comprehensive managed services offerings for health systems. Optum Insight continues to accelerate its integration activities and investments in services, capabilities and product offerings to care providers and health plans.
Optum Rx’s revenue growth of 15% in the first quarter resulted from advances in serving new clients and further expansion of its specialty and community-based pharmacy offerings. Adjusted scripts grew to 378 million compared to 352 million last year.
Page 4 of 6



About UnitedHealth Group
UnitedHealth Group (NYSE: UNH) is a health care and well-being company with a mission to help people live healthier lives and help make the health system work better for everyone through two distinct and complementary businesses. Optum delivers care aided by technology and data, empowering people, partners and providers with the guidance and tools they need to achieve better health. UnitedHealthcare offers a full range of health benefits, enabling affordable coverage, simplifying the health care experience and delivering access to high-quality care. Visit UnitedHealth Group at www.unitedhealthgroup.com and follow @UnitedHealthGrp on Twitter.
Earnings Conference Call
As previously announced, UnitedHealth Group will discuss the company’s results, strategy and future outlook on a conference call with investors at 8:45 a.m. Eastern Time today. UnitedHealth Group will host a live webcast of this conference call from the Investor Relations page of the company’s website (www.unitedhealthgroup.com). Following the call, a webcast replay will be on the Investor Relations page and at https://uhg.com/Replay through April 28, 2023. This earnings release and the Form 8-K dated April 14, 2023, can also be accessed from the Investor Relations page of the company’s website.
Non-GAAP Financial Information
This news release presents non-GAAP financial information provided as a complement to the results provided in accordance with accounting principles generally accepted in the United States of America (“GAAP”). A reconciliation of the non-GAAP financial information to the most directly comparable GAAP financial measure is provided in the accompanying tables found at the end of this release.
Forward-Looking Statements
The statements, estimates, projections, guidance or outlook contained in this document include “forward-looking” statements which are intended to take advantage of the “safe harbor” provisions of the federal securities law. The words “believe,” “expect,” “intend,” “estimate,” “anticipate,” “forecast,” “outlook,” “plan,” “project,” “should” and similar expressions identify forward-looking statements. These statements may contain information about financial prospects, economic conditions and trends and involve risks and uncertainties. Actual results could differ materially from those that management expects, depending on the outcome of certain factors including: our ability to effectively estimate, price for and manage medical costs; new or changes in existing health care laws or regulations, or their enforcement or application; reductions in revenue or delays to cash flows received under government programs; changes in Medicare, the CMS star ratings program or the application of risk adjustment data validation audits; the DOJ’s legal action relating to the risk adjustment submission matter; our ability to maintain and achieve improvement in quality scores impacting revenue; failure to maintain effective and efficient information systems or if our technology products do not operate as intended;
Page 5 of 6



cyberattacks, other privacy/data security incidents, or our failure to comply with related regulations; risks and uncertainties associated with our businesses providing pharmacy care services; competitive pressures, including our ability to maintain or increase our market share; changes in or challenges to our public sector contract awards; failure to achieve targeted operating cost productivity improvements; failure to develop and maintain satisfactory relationships with health care payers, physicians, hospitals and other service providers; the impact of potential changes in tax laws and regulations (including any increase in the U.S. income tax rate applicable to corporations); increases in costs and other liabilities associated with litigation, government investigations, audits or reviews; failure to manage successfully our strategic alliances or complete, manage or integrate strategic transactions; risks associated with public health crises arising from large-scale medical emergencies, pandemics, natural disasters and other extreme events; fluctuations in foreign currency exchange rates; failure to attract, develop, retain, and manage the succession of key employees and executives; our investment portfolio performance; impairment of our goodwill and intangible assets; failure to protect proprietary rights to our databases, software and related products; downgrades in our credit ratings; and our ability to obtain sufficient funds from our regulated subsidiaries or from external financings to fund our obligations, maintain our debt to total capital ratio at targeted levels, maintain our quarterly dividend payment cycle, or continue repurchasing shares of our common stock.
This above list is not exhaustive. We discuss these matters, and certain risks that may affect our business operations, financial condition and results of operations, more fully in our filings with the SEC, including our reports on Forms 10-K, 10-Q and 8-K. By their nature, forward-looking statements are not guarantees of future performance or results and are subject to risks, uncertainties and assumptions that are difficult to predict or quantify. Actual results may vary materially from expectations expressed or implied in this document or any of our prior communications. You should not place undue reliance on forward-looking statements, which speak only as of the date they are made. We do not undertake to update or revise any forward-looking statements, except as required by law.
# # #

Investor Contact:Media Contact:
Zack SopcakMatt Stearns
Senior Vice PresidentSenior Vice President
952-936-7215202-276-0085
zack.sopcak@uhg.com
matt.stearns@uhg.com
Page 6 of 6




UNITEDHEALTH GROUP
Earnings Release Schedules and Supplementary Information
Quarter Ended March 31, 2023
                                        
Condensed Consolidated Statements of Operations
Condensed Consolidated Balance Sheets
Condensed Consolidated Statements of Cash Flows
Supplemental Financial Information - Businesses
Supplemental Financial Information - Business Metrics
Reconciliation of Non-GAAP Financial Measures






UNITEDHEALTH GROUP
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(in millions, except per share data)
(unaudited)
Three Months Ended
March 31,
20232022
Revenues
Premiums$72,786$64,070
Products10,2679,340
Services8,0806,372
Investment and other income798367
     Total revenues91,93180,149
Operating costs
Medical costs59,84552,523
Operating costs13,62511,401
Cost of products sold9,4058,487
Depreciation and amortization970788
     Total operating costs83,84573,199
Earnings from operations8,0866,950
Interest expense(754)(433)
Earnings before income taxes7,3326,517
Provision for income taxes(1,558)(1,369)
Net earnings 5,7745,148
Earnings attributable to noncontrolling interests(163)(121)
Net earnings attributable to UnitedHealth Group common shareholders$5,611$5,027
Diluted earnings per share attributable to UnitedHealth Group common shareholders $5.95$5.27
Adjusted earnings per share attributable to UnitedHealth Group common shareholders (a)$6.26$5.49
Diluted weighted-average common shares outstanding943954
(a)See page 6 for a reconciliation of the non-GAAP measure
1


UNITEDHEALTH GROUP
CONDENSED CONSOLIDATED BALANCE SHEETS
(in millions)
(unaudited)
March 31,
2023
December 31,
2022
Assets
Cash and short-term investments$46,497$27,911
Accounts receivable, net22,41417,681
Other current assets24,98423,477
Total current assets93,89569,069
Long-term investments46,88443,728
Other long-term assets142,900132,908
Total assets$283,679$245,705
Liabilities, redeemable noncontrolling interests and equity
Medical costs payable$31,809$29,056
Short-term borrowings and current maturities of long-term debt9,9313,110
Other current liabilities74,74257,071
Total current liabilities116,48289,237
Long-term debt, less current maturities60,65754,513
Other long-term liabilities15,91815,608
Redeemable noncontrolling interests4,8014,897
Equity85,82181,450
Total liabilities, redeemable noncontrolling interests and equity$283,679$245,705

2


UNITEDHEALTH GROUP
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(in millions)
(unaudited)
Three Months Ended
March 31,
20232022
Operating Activities
Net earnings$5,774$5,148
Noncash items:
Depreciation and amortization970788
Deferred income taxes and other(263)178
Share-based compensation362299
Net changes in operating assets and liabilities9,484(1,094)
Cash flows from operating activities16,3275,319
Investing Activities
Purchases of investments, net of sales and maturities(2,319)(1,632)
Purchases of property, equipment and capitalized software(760)(555)
Cash paid for acquisitions, net(7,826)(1,231)
Other, net(115)(255)
Cash flows used for investing activities(11,020)(3,673)
Financing Activities
Common share repurchases(2,000)(2,500)
Dividends paid(1,537)(1,363)
Net change in short-term borrowings and long-term debt12,3752,048
Other, net4,3524,119
Cash flows from financing activities13,1902,304
Effect of exchange rate changes on cash and cash equivalents51157
Increase in cash and cash equivalents18,5484,107
Cash and cash equivalents, beginning of period23,36521,375
Cash and cash equivalents, end of period$41,913$25,482
3


UNITEDHEALTH GROUP
SUPPLEMENTAL FINANCIAL INFORMATION - BUSINESSES
(in millions, except percentages)
(unaudited)
Three Months Ended
March 31,
20232022
Revenues
UnitedHealthcare$70,468$62,595
Optum54,05943,259
Eliminations(32,596)(25,705)
Total consolidated revenues
$91,931$80,149
Earnings from Operations
UnitedHealthcare$4,343$3,798
Optum (a)3,7433,152
Total consolidated earnings from operations
$8,086$6,950
Operating Margin
UnitedHealthcare6.2 %6.1 %
Optum6.9 %7.3 %
Consolidated operating margin
8.8 %8.7 %
Revenues
UnitedHealthcare Employer & Individual - Domestic$16,544$15,822
UnitedHealthcare Employer & Individual - Global2,1632,133
UnitedHealthcare Employer & Individual - Total18,70717,955
UnitedHealthcare Medicare & Retirement33,00629,100
UnitedHealthcare Community & State18,75515,540
Optum Health$23,004$16,682
Optum Insight4,4963,219
Optum Rx27,41823,911
Optum eliminations(859)(553)
(a)Earnings from operations for Optum for the three months ended March 31, 2023 and 2022 included $1,776 and $1,366 for Optum Health; $907 and $847 for Optum Insight; and $1,060 and $939 for Optum Rx, respectively.
4


UNITEDHEALTH GROUP
SUPPLEMENTAL FINANCIAL INFORMATION - BUSINESS METRICS

UNITEDHEALTHCARE CUSTOMER PROFILE
(in thousands)
People ServedMarch 31, 2023December 31, 2022March 31, 2022
Commercial - Domestic:
Risk-based8,025 8,045 7,950 
Fee-based19,325 18,640 18,460 
    Total Commercial - Domestic27,350 26,685 26,410 
Medicare Advantage7,545 7,105 6,890 
Medicaid8,380 8,170 7,810 
Medicare Supplement (Standardized)4,320 4,375 4,355 
     Total Community and Senior20,245 19,650 19,055 
     Total UnitedHealthcare - Domestic Medical47,595 46,335 45,465 
Commercial - Global5,295 5,360 5,500 
     Total UnitedHealthcare - Medical52,890 51,695 50,965 
Supplemental Data
     Medicare Part D stand-alone3,380 3,295 3,360 

OPTUM PERFORMANCE METRICS
March 31, 2023December 31, 2022March 31, 2022
Optum Health Consumers Served (in millions)103102100
Optum Insight Contract Backlog (in billions)$30.7$30.0$22.8
Optum Rx Quarterly Adjusted Scripts (in millions)378370352

Note: UnitedHealth Group served 152 million unique individuals across all businesses at March 31, 2023.
5


UNITEDHEALTH GROUP
RECONCILIATION OF NON-GAAP FINANCIAL MEASURES
(in millions, except per share data)
(unaudited)
ADJUSTED NET EARNINGS PER SHARE(a)
Three Months Ended
March 31,
Projected Year Ended
December 31,
202320222023
GAAP net earnings attributable to UnitedHealth Group common shareholders$5,611$5,027$21,800 - $22,400
Intangible amortization388281~1,565
Tax effect of intangible amortization(96)(69)~(390)
Adjusted net earnings attributable to UnitedHealth Group common shareholders$5,903$5,239$22,975 - $23,575
GAAP diluted earnings per share$5.95$5.27$23.25 - $23.75
Intangible amortization per share0.410.29~1.65
Tax effect per share of intangible amortization(0.10)(0.07)~(0.40)
Adjusted diluted earnings per share$6.26$5.49$24.50 - $25.00
ADJUSTED CASH FLOWS FROM OPERATIONS(a)
Three Months Ended
March 31, 2023
GAAP cash flows from operations$16,327
Less: April CMS premium payments received in March(11,196)
Adjusted cash flows from operations$5,131
(a)Adjusted net earnings per share and adjusted cash flows from operations are non-GAAP financial measures. Non-GAAP financial measures should be considered in addition to, but not as a substitute for, or superior to, financial measures prepared in accordance with GAAP.
Adjusted net earnings per share excludes from the relevant GAAP metric, as applicable, intangible amortization and other items, if any, that do not relate to the Company's underlying business performance. Management believes that the use of adjusted net earnings per share provides investors and management useful information about the earnings impact of acquisition-related intangible asset amortization. As amortization fluctuates based on the size and timing of the Company’s acquisition activity, management believes this exclusion provides a more useful comparison of the Company's underlying business performance and trends from period to period. While intangible assets contribute to the Company’s revenue generation, the intangible amortization is not directly related. Therefore, the related revenues are included in adjusted earnings per share.
Management believes the use of adjusted cash flows from operations provides investors and management with useful information to compare our cash flows from operations for the current period to other periods, when the Company does not receive its monthly payment from the Centers for Medicare and Medicaid Services (CMS) in the applicable quarter. CMS generally remits their monthly payments on the first calendar day of the applicable month. However, if the first calendar day of the month falls on a weekend or a holiday, CMS has typically paid the Company on the last business day of the preceding calendar month. Adjusted cash flows from operating activities presents operating cash flows assuming all CMS payments were received on the first calendar day of the applicable month.
6
EX-101.SCH 3 unh-20230414.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.DEF 4 unh-20230414_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 5 unh-20230414_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Document Period End Date Document Period End Date Pre-commencement Tender Offer Pre-commencement Tender Offer Soliciting Material Soliciting Material City Area Code City Area Code Entity Address, Postal Zip Code Entity Address, Postal Zip Code Entity Central Index Key Entity Central Index Key Document [Domain] Document [Domain] Entity Address, City or Town Entity Address, City or Town Security Exchange Name Security Exchange Name Title of 12(b) Security Title of 12(b) Security Written Communications Written Communications Document Information [Line Items] Document Information [Line Items] Local Phone Number Local Phone Number Trading Symbol Trading Symbol Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Entity Address, State or Province Entity Address, State or Province Pre-commencement Issuer Tender Offer Pre-commencement Issuer Tender Offer Cover [Abstract] Entity Emerging Growth Company Entity Emerging Growth Company Document Information, Document [Axis] Document Information, Document [Axis] Document Type Document Type Amendment Flag Amendment Flag Document Information [Table] Document Information [Table] Entity File Number Entity File Number Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Registrant Name Entity Registrant Name EX-101.PRE 6 unh-20230414_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT GRAPHIC 7 optumlogoforearningsreleasea.jpg begin 644 optumlogoforearningsreleasea.jpg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end GRAPHIC 8 uhclogowithra.jpg begin 644 uhclogowithra.jpg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end GRAPHIC 9 uhglogoa.jpg begin 644 uhglogoa.jpg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end XML 10 R1.htm IDEA: XBRL DOCUMENT v3.23.1
Cover
Apr. 14, 2023
Document Information [Line Items]  
Document Type 8-K
Document Period End Date Apr. 14, 2023
Entity Registrant Name UNITEDHEALTH GROUP INCORPORATED
Entity Incorporation, State or Country Code DE
Entity File Number 1-10864
Entity Tax Identification Number 41-1321939
Entity Address, Address Line One UnitedHealth Group Center, 9900 Bren Road East,
Entity Address, City or Town Minnetonka,
Entity Address, State or Province MN
Entity Address, Postal Zip Code 55343
City Area Code 952
Local Phone Number 936-1300
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, $.01 par value
Trading Symbol UNH
Security Exchange Name NYSE
Entity Emerging Growth Company false
Entity Central Index Key 0000731766
Amendment Flag false
XML 11 unh-20230414_htm.xml IDEA: XBRL DOCUMENT 0000731766 2023-04-14 2023-04-14 0000731766 false 8-K 2023-04-14 UNITEDHEALTH GROUP INCORPORATED DE 1-10864 41-1321939 UnitedHealth Group Center, 9900 Bren Road East, Minnetonka, MN 55343 952 936-1300 false false false false Common Stock, $.01 par value UNH NYSE false EXCEL 12 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 13 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 14 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 15 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.1 html 1 22 1 false 0 0 false 0 false false R1.htm 0000001 - Document - Cover Sheet http://www.unitedhealthgroup.com/role/Cover Cover Cover 1 false false All Reports Book All Reports unh-20230414.htm a2023q1exhibit991.htm unh-20230414.xsd unh-20230414_def.xml unh-20230414_lab.xml unh-20230414_pre.xml http://xbrl.sec.gov/dei/2023 true false JSON 17 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "unh-20230414.htm": { "axisCustom": 0, "axisStandard": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 22 }, "contextCount": 1, "dts": { "definitionLink": { "local": [ "unh-20230414_def.xml" ] }, "inline": { "local": [ "unh-20230414.htm" ] }, "labelLink": { "local": [ "unh-20230414_lab.xml" ] }, "presentationLink": { "local": [ "unh-20230414_pre.xml" ] }, "schema": { "local": [ "unh-20230414.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] } }, "elementCount": 27, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2023": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 22, "memberCustom": 0, "memberStandard": 0, "nsprefix": "unh", "nsuri": "http://www.unitedhealthgroup.com/20230414", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "unh-20230414.htm", "contextRef": "i5fbbc7f338ed490c8d706d393dc1d997_D20230414-20230414", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0000001 - Document - Cover", "menuCat": "Cover", "order": "1", "role": "http://www.unitedhealthgroup.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "unh-20230414.htm", "contextRef": "i5fbbc7f338ed490c8d706d393dc1d997_D20230414-20230414", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.unitedhealthgroup.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.unitedhealthgroup.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2023", "xbrltype": "stringItemType" }, "dei_DocumentDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Type of the document as assigned by the filer, corresponding to SEC document naming convention standards.", "label": "Document [Domain]", "terseLabel": "Document [Domain]" } } }, "localname": "DocumentDomain", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.unitedhealthgroup.com/role/Cover" ], "xbrltype": "domainItemType" }, "dei_DocumentInformationDocumentAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table.", "label": "Document Information, Document [Axis]", "terseLabel": "Document Information, Document [Axis]" } } }, "localname": "DocumentInformationDocumentAxis", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.unitedhealthgroup.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_DocumentInformationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Document Information [Line Items]", "terseLabel": "Document Information [Line Items]" } } }, "localname": "DocumentInformationLineItems", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.unitedhealthgroup.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_DocumentInformationTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package.", "label": "Document Information [Table]", "terseLabel": "Document Information [Table]" } } }, "localname": "DocumentInformationTable", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.unitedhealthgroup.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.unitedhealthgroup.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.unitedhealthgroup.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.unitedhealthgroup.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.unitedhealthgroup.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.unitedhealthgroup.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.unitedhealthgroup.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.unitedhealthgroup.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.unitedhealthgroup.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.unitedhealthgroup.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.unitedhealthgroup.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.unitedhealthgroup.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.unitedhealthgroup.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.unitedhealthgroup.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer", "terseLabel": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.unitedhealthgroup.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer", "terseLabel": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.unitedhealthgroup.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.unitedhealthgroup.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.unitedhealthgroup.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.unitedhealthgroup.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.unitedhealthgroup.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.unitedhealthgroup.com/role/Cover" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425", "role": "http://www.xbrl.org/2003/role/presentationRef" } }, "version": "2.2" } ZIP 18 0000731766-23-000026-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000731766-23-000026-xbrl.zip M4$L#!!0 ( %LPCE;@3,\R#C, #/0 @ 5 83(P,C-Q,65X:&EB:70Y M.3$N:'1M[7UK<]O&DO;W]U?,VDZ.4P7"Q)6DG9,J199C[;$D'TG95-XO6T-@ M2.(8!!A<)#._?KMG !*\WT60F+.U#D4"<^GNZ>GN>:;[Y__Z>'?Y^.?7*])+ M^C[Y^ONO7ZXOR:O:NW=_&)?OWGU\_$@^/]Y\(:9:U\AC1(/82[PPH/Z[=U>W MK\BK7I(,WK][]_S\K#X;:AAUWSW>O\.FS'=^&,9,=1/WU2\_XS?P+Z/N+__O MY_^JUDL1=TR1\NB[^16BU[ZC(<#".OVTN(7M<-\D<8 M??.>J/@]\1*?_9*W\_,[\??/[W@G/[=#=_C+SZ[W1#SWGZ\\W:&V:=I6DQJ6 MZ3"]Z;)6J^4T79M0?+AV7.3 MWGNM7O_A%7_NEY\[89! 9Q&\+#Z*-F9:2MCWI$9]KQN\Y_.!][U^EU _^>>K MM-?UPVY(U?\,NJ]('#DS7XDVLI'8K<'W#WT:=6%P[3!)POY['-L3BQ+/H7[6 M"^]0_)P-VZPW!]_GSE*TE82#]T8+6BJ,U0'*LNB5F&?^O!/Z8?3^=9W_[P/^ M4NO0ONZ_AYX( Z?&9"F1WZ+PG1 [MD@C)*8?/*B."'_3FD$@Q(2<<_BU$_B2>K/ MGYNN0?\#ZKH@9S6?=9+WAEW/I^L%+DSU?4UK#I(]3;<^-5US>KH6BM&/KYNZ M;G_()[#7CGD[[[T$>.DLISP,99(TFJE:2(E[]L2"E,4D[) W+4UMD5\]WP<% MH !OV#/1K!_(GXQ&M3N0OQI^6H<5MN3$QIRXHE$ 7\:D$X5]LLA7V#\>>C1BRIA7H^?>V*INCQ]9AR]&_6 TGS?15[_<7-_> M7CW>W?[K0B$W7A"HY.W%(/)\HID*WQE_(@?AQTI!T+0/9,X6_O;VSX:;:/?7G#AU#_M%0)N,5K@[A] *#-=GM O[-6=%XP-)@V<*.[.@ M8;_O)=SF3D)XHR.^[H>P*GJ"5S"/)\^!W1X>X-\/6#CP&:=GL.)<'ZS0J66EK&_":YY 3".38GX,XV)#[+; M'@IRYRS(2>U$(1(1WAO+ F< ?@4\'-!@F'$W!DK!GR[G"1W0M@<$]P3[D-($ MZ(ZO]44/^'+$>@R6TA/SARIY'+<(8T5'#!>5!TNOD_H^&8(U1P*6$)9KQC!- MP*G[ANV_T0U5M_)/#0O&#U*,^I(/EN9:=>)]_C2HY;KX9*GU^OB].0MURO/A M/M@@%![H^XCY%(5DQBO+W\JGN4IJ=!S(5]IE1$-9 MMQ=28M$ %_J@XM]>E#8M<<()0"=-!S-[G'SZX7CSPZ?"]%W"F\Y>V&:QA6[#FN*61 M %T3-^\YXX\JK)!WB3OG1\. U;;D]Z4O+_NQ(1O.?S1R]JQ^]1WG8#0EQKIX M(L'MUH]!,?_SE::_FA(P8=T.0"F%/NR@N3;*?D5S=/;'S#)^KP^^DREAQN:F M94^(W4M9M%RO9&$=?T@^>0$-'&@0;7#8POKPU]@*SR@[HH\Q39Y(-+H=?>I( MG>4\TJP9'LV,80&+YO92;*CU:JRG%S),:)^CLTP,R65.*%S:]RDXH!$^]>J7 MQU[$&+F!%GHQN8+OW=WYMP&+=.UP+#).B$7@)]+(Z1%#4]:@OYS/R\_G(W-8 MOPTF\'I3VM\2T>I:N*.M^Z40CCJV4$ M<1S&.IT/ZRVW,IAN,XXK5V+Y(=$ZI%Y$@W(IZ_GS% =@[:EP_;E.MEE7M>I, M5E>;^YCL'C?HI6[&3/\=_K^35R6+3CFWXDE&D],0P!T7VRG-M:'6*S-7>\<= M8W)=O[Q>.1,3Y98EY(9'7,]]*[-5[8?SGZ-Q]G.TU.9.<]R?QFCN8(B,ST_F M1V-W#S%L/0+9Q\;#Z$:1;[,$( S,7/ M9)C-;H[0Q-/VHN_*C_9K(4(V\9."I_]^RG$$P"(6Q5['8RYQPQ285W.]KI<4 ML#8@);UE@)MU %,<#"QYOH3GGV89RR:>U4-, ;7,57 ?0=2 2ESD M^LQ%,TC0G(L;:H"FKNH_".A0! P!]=*$OWT*;PM]XJ8,OVWCI0[$A/6][RKY M2(7PJ3"-0 (*P]*Y?,(SVGR(%3ZB MDD_T*8QX)_DD0 9!:AAQ04'ZX8!#X>8V@&!WLU&'80MU61S:&UL?_[!BB&_T MULRS?.G0;CC9I4JD'!]2CC-ER14?_"8D&?6B"69V ?S&%2%\J>.7@I%S9'DA M'@^UJ@=[KPMO/[&8HRTY[ VQD3X.0<#CXG2 ^%?229,T&J$\0_YE&G 0GP)K M!'P0ZOM#A$'&X,""8AUW,(A"-W5 >7K)D%#W"4$24AON28HX;K\SQNT7]MH, M4SE/R K7 7)#"Q[6U68M\?I@CR$6$D0M[,->>O4]M[BPL6S[ X$4*.[+FP=4 MD4)\(N8PV"-=U+P"%^KBD_PH7!DC+9W%8Q[?-2B,JZZV9L:E%)'6?..=)^49 M#'020!HQ$.4 QO'&4*U1/R#Z'-S9"WT7 <-SU6W2 Y.VVT/;TP/I*<@]DT)O98L5V\Q8SZ#A;N$KS.6)'PN1E8WL& MEE;'RV#/#!'('K^H2 =X#P$-*%AWZ3)#MT)X5?T\\*ISM.2BJY %B*J#>%1< M)M$D3G7V^TFPJKT=6!4O^ZRZP8FZ_47U]K2;@*L'EW&<7RK@7[99P#K<\O?# M-NYIRLC0AQT'UWU*?;'N67_@AT-8D0K_\X8;;QFL7/SAN5E[CDFHQ21$ MA<,MEJS1E9S]78\?+ J80 M[$XD90M2'K4,.WGB-0X-="5X>2^EQ1RG$AO%O_3[[,(#^@XZK2/B+MA]C9''K' "Z,< MLS!*E1@+P--8J)B 41F-N8860@2CS(6X!X%/!_XC:B,9YQQ$W!T-0F@^$MP'!L":_,82$#WJ3J[P>9D5 M4- MBLEAQ2M* RK0846T&?Y= (YU\99*P.&S"O&]#FSO#L=8Q=EF@,IH O4%.HD7 MH)A2*5[ \1M)=J>&^D-@D'@U84XO "IVN:H:>LR'YH 4_*J!%\1(#NA=7(7I M,7\09W RT#4P.NJ/)AL/XX3U,1-J#A81F9)!JKR^][=([QJ- &;*&"3&OT9\ MF!C2),HMGUL!8K8)?$S"QB][XBNQ8A(KMLJ5F:NYG\2>$BLFL6*;X:A:9X^C:E0@Y65SQSG*E)%>>V16ENXQXQ(O[#DZ@LX M4N-$:X;Y S\&G\R)EW%:(6[D02N8@F4,ZID ZA$>^9K-"TFCB 9=QH_^!5YK MJIQP 2S%$4LQ3X?5$2?FQ M18NG3*6^.)0/:@(6 "TGB<"12;';G]A="ZC%"&V2RQ]J?C_L%F0.I,G(E(91 M'RN!R=2316SA6 I1.G (228MESV4,E) L'&HVTA6)VKMDCX-:)>Y4Z(E7/\P MFH2!@'1,S&LDK]-Y!!''YH'EUA51 _B))P/,D2W%!(0Y(LYA'#93J!2,3V9H MO<*@\OK!(W -?RX;I@ *2@G>GP3??Y\1WCPC9(?G;YZ+#Q5Z+<]9F6> +*(? M ]CT0/5P$4 &=C!+J< #C?4>BE$\8 A!P$22'!,U"8D=]&C4I\ZP"(2]R+,. MQD[D#9)X!.$U&LVY:5,-:XSG'26*79;UM$)@2_.>&"5Y>_OGPY6 __U^^_DG!$;3"5!DGH&NUF8"^BW2;W+H.84E M%L=9WDV$'.8VDX^[D&C% P6 ?^8Z'1[JTV^LF):S.;"6PM?%,N("EY M/DZ:4([F#)^YNLDF(1+B!OEN--Z;1GE*NZGGTCR17A*",XA?#[F-)C9/F#TF M]A-S$K.= T;G>@[IWDE]GW![$E=H1IT\E2&F_P-/#PUSEX* MNK!"9X\.PB[# 'TN7!>7U/?+J+,O,#\P>_+"-/917P5A"L-UE7G+DM^+ 0WI MI MN(F6^J8*W7L"FSQ1@EA4\O_F"MCUZ 3EE'(2.NI488?:"I K3/R1XQ1,X+MK09 MLGX9K5%8CJ+Z>TDRB+F\_?C:;(A_TEX7BU_8+ MX=14]&T8U'Z[N/A: *Q?C^_&E%%11E\<- %13PI3'/Y. QZ%!FF"/J -\)+!=HQX20>4 MHT$BWL4VA6XF#PE(8,P+ ?1AV@XE;WG HOX!Q\L_:A] BUQ@=ND0FO4]FA0B MF"MFEDV@CPK?]:")Q!]F;CJW7J=>[0/9TNQV9F&N/!CF9(+--1F^C+&L-)BN M4L WD8P!IR;SH!;PTFOM"^S".$W.'!Y1*Z>\X\VL?(3@G8!CUD=I4I!Y_\&K MPJ";E+&7!"HK-S$PQDB](&>YY M#L@_BDV0,+P.P<4.?4Q:N&W+A21K-*8=\(]HU ZCO$$N;S'7IMFS'>;BVB$Q M<])(1"]]^BQB_."JNG'>6AN\*7#SE+RI[&OTN9QD^ELQQIEG,]I-?P^C]V I MS_D%+W[B#C[]?4;AZ:\QB#KSG>#2]-=Q+TQ]-_^2WT_W0&@HC^.!*A)$PL(9 M"7B;9(I!!_$U\@R9RA+TD/%W_A9.DHAX3UZ,.3A#T$;K=!,D>B;(W MV18;QOS:?Y*%T;E4"F;"<%PV@'YQHIFM! /'2B;\?K[HDW2HPXWDT172['IE M&A$1">O(3&6A]XK!4>IR Y M=)#'BN%)%TR/81:W'U6!&=6-$4=EXSNQR,YN1/O9T MCSN_%*YR46(4&A"4B MXC@USM_+!EP<'Y(;V9V5H^&]8!P'#^A W0BA MKGY,+7/][]]\@J\ED7C\OX MY(B(\N*^DNVW4PW':3N/(5(URA'@AO"KIUD MI]8,;8Y<;XK>982<$4M&R#4V1-UAMQ%XZLSVTN' MJ!KY#B*T$8IJ0>BY!9R%F+E\,;>HP#+=-%_9@SS'(>PA29X>!=LN) 0=B4W MD_-CIHE3^$Q%P0A8(DI%\CT/1A87\AT.I09_9#K&=":789SGBH\-U&UK:",9EO*BA1FVTXV MG1B:BL5V-LS4)#"@YPVR*'AQJ\G3) QZPQ@KY>!. WLI+V(E&"6$(J/T.* ^ MUM#CLF2#$,MEH2E0H%="OXL-312N&0D$>3MF#)Y-C#B0^SKJ@YH5'.-M"+TG M-A/T0KC(18/,(H]_$@/*6XG%^7J>\T!, MR@\9GVE,3AU]TLA4-A$Q3!L^P7 M+#;$MR>Q.3]YX#?.4?Y\]X]3'@/ PX$A%Y$L> =2 L+CB6-8+BOH.*(1D;W( MA5$PQ.?L6CZ6/6,CJP/-'A!X1)0 M(!@>!)OINQ -SLXY*R/A"T?)!1NS6*!,*T7#"J4C(V]F5'QCPSRQ1W9DQ;Z# MTD)-$(^W_3'8@6 )Q4[H>^%4/@V4(!!G+Q+6E=B/NV'H\EB;,%L3&+^'$@BD M9W/6)"R1!"%$\%]0I8R? P; ,@/N9B9^!/K 1_GH(DC9:&&-EBA-D;1$'$:6ILIIXH\JP([WG M(Y>G7_YKE/8@+_675SDDSM#!([Y,Q2+>95SZC[LQJ+'CG&\(44 #*PF=;^NA MJ8X2?0(WZ@D/7T'Q8RPJ1+^E1\&,!>E5R1^L>#80L\R8S>J>Y8(LHIR>J<% MSL JXWG&,'0:$ZU>^Y>"__Z;=]:L_4LEOPXSKX9K&N#M8L^41PN0/%T0$/"Q MF>!T=@Y26,=".XN9<+,>+86TC6XS"B6GE3)M@.!S8#'T!T)W<5+BB^AP>@Y6 MI>9+&_4E=[M 2KDK/>.G(OV?<,U/^ZC"&\UT8^:5X]X?$7X&/"^LPAW*82[/ MH$W$AH' &^%1@9O\9Y@2X?USXO!$2.C,\;4A-AIDP6*Z*EDP!GQWBN=(&'<< MQ5,PUBW.QT6N)3<32>&.<)^1!VV ..F /YQMC3QPOBS0H.!>P 8)=A9AIK:ZINM]9J-KOFL<6U_Y)4EQN=,EUBN,Y) M> AK@X0&N^6O* D1,#Q%%U/@A)@\_P+4_P=GG3R$ X=^.U_6SI_Z#=@^Y"'! M(]KXO)CZ(++)_@_ZV%_!,N!QEJJQ=S413I[/+4NOM0R[UM UJVKLU>MZ36_8 MM7J]:1V)JT;=TCKZWF?V-ZAD->8JFG MQ]S4S\(;#^F@@+M?!Y=UW.EDZ4]%LDS"TQS^^%JSZQ\,36#N7GS<*Q5@P^1 M;QQD=?Y=R(:]7NI#B'),;MDSN0_[--B517N_WC3]R?0EHI ^(0I)DGLW M
V=G\^]IK4R*\C/(4D]PN2F]PP+*$CB;XCT>]GH.QS;AO<""SZ!L1>>BBS MW5OKM'APYW;/'F+C>![BH:UZ_52\P/4&>GEW^_'J]N'J(X%/#W=?KC]>P,#) MPR/\Y^;J]O&!W'TB=U^O[B\>K^&!Q;B(EYK&_+C(6R_(4T&,CXHQ6Q#'>' ( MS4]E'7H:<)@8/L(R5=%HM53<;VYP(-TQ5:S6V.KI=_IMA;O?FLL%J=;51 M7^] N!R#U?1]GEYO$&D^BZ(LY+LX0$E'\?6?UW261\ H*A MU17=;DA"K2142S','=?/R6Q!#]D-/ZE85Y*JJ=2;=4FGE72R%:.QD?5]PMO/ M]?C*V_CBGKA4*17M2NHU6DU)I954,J8V[?/=C);C8![Y9<=HCY7_=E'$"_W8 M4Q"IEJ:T#*VT)#P1*C;KBF:VSFZGFQ^ NIM(H7!T?VMOH4+IB39V.G(,67E54L!1:^ 3$0S,46]]N'56,4)IB MUK6*>!J7H6B498; MV@]A3']/WGV2BG?AFFIL%U6N%I4:S69%]J9UHF#A'NQ &LNS5JF.QX:18ABZ).*N M>YJE504(\36ON\-KGNR\%"NFM37%LIIR?UN+4H;=JLH.=\N2ZY M=>BD:Y7IADR!VOW'$FENW6\'8&[F$.LPP0/S=,\..I>5_%;NIU]=YA]Y$1%T%;U,ITHGB@5+777NRXEW(T7(-JRW5@\Q-P: MA3%A'OGB$HVQR'6<4%[WNB3[1):-;(Z$G;S\M(+"T@4 MBL4UH/F)))[CZG%YGE5#$WE&]S&=UJK9B#R!X\WSA?J5RV=Y[-E6 B8 MUZ'@->RQ*/Q4KE6L!1CD^5;[(LOJV=8<7[/\GS9)@*,6#3\T1:J1)/77BR\7 MMY=7Y.'SU=7CP]''OCHSJDR!6IJJF U3-9K;5<5*-DCK)0^@U D.FK9BM[?(*5HQ2>D-I:3M>L2YA-'S^ M;"\CHJA,@E-90[&952" M3AI%/-W@NK9(U;6N;BJMYG:+J6*$,A2S<9"S6H+_U9NE7%7B/O4>5I6$[HR/ M$0REN25V0E)Q?.&EI=3MJARY?@F#KO2^-J<;.%]-N;NM0RA#:>@[@NU/QO<2 MIJ(_6E/EV-9.0$HT4U=:=9F/9PU*&4BI@]Q>X>:BUBKERA+F8CF'B? M_95ZR?#8>GT]@%B)TE:O.\KS=4PF\E:3 1VBK!U;8YV"4C(TI5D_NFX_!4KI MX.A;]MEI[P4%I\;GK*!GHO!97%0$%9W'X/HT22.NWA$8.79B7-:6AT=K!-^V M+NU1+3H9BJ95)4?:Y-&1/S:@I'I>2;N&J33,[;(W58M05D.I-PZ";CB=\Z-= MEY8\_A@'F#1;,9LR;=JN^51;BFZNE,I\]>%C7;$M M">I;8]*7''23KY)4-2G#.A%T$M9K*D+,PI4;U$'OHD 60BCY-/Y/'P"/^YN;I] M?"!WG\CEQ<-G\NG+W1\RI8=,Z2%3>I1EL*5+Z=$ZJ7P6C[V(,7(#S_5BY0@$ZR< M2GB[6(_@V.[I*3B8VQ?6J1RA-BR>L#Y"K4UCAE/L M8UEVN6&M>2O%EE<-5E-);^V8%^=D,"SH/CL]&G1A=_("$H[")2(% =^Q) IS ML_MQYI8):4F^9.Y;-/#VP"T\(W/'#YYATHK!?7'&;!"AEPHIE)I&M M&/K1+Q><.A4MQ=#.;QN@ MD&:0IZ7&[V+J9T$ >5=LHT@ :B)9B'PMF\HV]/,K1;[&>AM$:$DE0X5C@@=] MGFT7LW[0@9? $/]F+FBG3O),H^W2ZU3,.F_8=1E]6X-.EF4=Q(OO!"Q?1S0VGJMMS)UMK)=$.KRD[&[SW+ZB7KBH9FR:UI M';/Y0%O3B8374CP>PIW*&SGW,L2VQT6HU/4M341)QS$=\5Z=<7[[W/PPVR13@V*KH%+2-KD"S1U?:IT$I:YI2YZ"7 M%Z#50!>[+'!C[MX?6R.?@GAHBF4TI!>R%J6,:2#?^>Y-8S@-HFGBA;FH]Y!U MNEKZ6-,5H[%=R;=J$0IV^,VNK9SPMB7#9AMEYC*LHV>[/0DZ:;O"7DXZ;,91 M:9V1HRY#9ONK:*9HK:-?%SIU*H(=4#L2BQGUM'S%9XZ!36K*FGAKP,G8C3F/M]^%Z14 M_&-Q:BJ6N5UV:TG%HG5;KTI^WLM%2U$A;=;U LP9PJ&#T'PHHYYKV%Z&8MC; M!6$J1BAM)EIUOKO?DF7&\+[[3@M,)H_=(&6-J2DM;:V$9Y+..R7IM68J1\W/ MT9N/IR)Y>,>B)_/PGE@>WH??OW[]PC/N7GPAGZYO+VXOK^'3]>VGN_N;B\?K MNUM2([_^_G!]>_7P<'4*>7@5#)HPT"^P^^!00.QD;MX]Y^9MM52[T=@V-6_= M/$BVV]9!LMU:S1,:K+U>'F&9FE>FYCT6B65JWJJGYKUG3RQ(93K>LPH&_!Z@ M%?.943_I.=M>M:T68N=-HZZ8]M$CVZ= *5M7K-:.<;63"5_?#9*T+X.MJT]J M3:5N;5>:JEJ$,@U%MPX";2KAZKGRO;X7\+201S]Z/0'9>&N@:I57T]>Z&L)+ MM!WW;LATZ,H#)S6 $38YY5^.&*)VHP.+#*U>"K8?B:;M>A&8E2B:[6R>EJ:T M# E&VI6,S;JBF>>W^S% MH:^6G?W&5 QSNV/XBA'*4!JM@V2O+^%"XNX\>4NEB;V:5B 76RZ@JM%)LS8Z M%3BD'Y(U4TY"76[A_7VFQ^V MJ5\6S5QB&=(5S9: D[7H9!B'B 66.;?G1DN.GYH?6VLO/,,]!1G3FDJC7M[B MTR=!PH;2LJIRS6MF>=XPU^,?Q/*\9XD7,:QG*A7\2F(:AE*O'QV#<@*$TEL* M?*C(L=C,$L,20BE\.;V]S9)5&-8@E 7>[]SE-14UU"P9-CQ% ME2+0W$*ER/6P.LBAX\8LPT'K!<[L>$(=72L&^;5DO6 MOUR#3I8UK_KEPE316196#-SB%;J)2W6&/7VISM!4:U\8NM:J^8A4M>,+K"_4 MYR0-]+IJZ3CEJP67^4@GC(A8TO@IZ3'X?TSGV0]Y.D_&TWF.4GD23$3)T]=C MAD7B!8Z?X@-O-*71L/D/;["$J5UH5[A]/[ZV6A_(FU:](9YJFHW",YE-*Q[* M6JG;=?&Q9;0*C]Y_5TC$X@'#4FO,'ZH+'Q[N;JGGR] MO_MT_>7JZ.->G%X]Z84IM.$NR:5>TDSES9:^3:9R2U<;^K8)OI5 M44G>-!7;W%1G2-Z\%&],^XB\.8=<7_78IOO:_G^I15IO M*,:V)LHF$9!3,2W/A*N(.=W2)Y!<+3%73:VL:_5\\9BC^WL7[A/E=:>/[6B< MAS@W%&OCN,46L?=3L8+/A:E:73+US)AJ*\W6EFY/^?:=$OI$R_8=3YY1K!\( M-YI'C+9*UBQCC=:0K"DE:QI* MMG+4.05>3<7094R\K*QIR*.DLK+&.B)KSL$RW^RT8OK,0J2DP1M"#RSPPNC8 MEOQY>*-Z7=&W!;R4)L8@N3J+2;#E0=098H.:2:(V/EK/4A8> M-F]H9:*G9D.Q6C(F?FYB#5679YZE,?UD!['/H5;+S%@0W)U6ZYJBBW]R+/C M:EUIE=WCR =RO!SGA9D:,!SB<\F75RDRO9Y=6U*K;!TA^J1N+.]TA M^673UD\G4^>)#7:]'*AKIA4]3%FO.3M%.9,URGR=,E]GI0K_B&,1A4EW1:32== M5YN5LK+NOY-_IS0":]((G+96N=@/P8#5F$<1TJ;:>+ M*D8E:XZ_-Q.8719'?<'J>;=APGC1A E,&_D-:#\@L7#<-$O/E0E) ^^OE!$O M@&%Z;DK]F% G"F/XC^^3=AI##W',X,]DJJ1=Y8O(624L(ER[P\!['3"0XAX""%R:T,75V(X\]#2@J8NJ M;MUZ<5CCM+!.['GB_Z(2=/'QOW]_ &$GMU>/Y.KB_O;Z]K<'/+DB#Y\O[D>U M^O8PH(;:7&-$CF3,R M-:MWTO0U"O_#''3^_V0T*M"D> JW26CDX,#@C4+=I:'SFD>Y>ZNK=@;TVO.Y M[SF0Q*A(D)+[,P%+".BD (:* 8$D\MJIL-F2<%Z\P0G[_3 03D0O]('9\;'C M3:=^0O?&4FQ-DU3JCW M:#^$T?Q-T5N6QWJK0^G-[8YEJD4EO;F=@J\6E7Y\K>GV!TVQ;*LB-M@C_4Y@ MI. +3)E$5%UUX#HR9A"A8#H&*RZY]!HM;:RMW55J\L+CVL1JMZ0A%H[/ H[ MW:[QT265X+16*?73*!JZ9W=M_Z[UXE16)Q]YLE7=EE0^O*MH'MU$.W\JZZ9J M";R-IX[\(OI93DPLOEQ<-G\NG+W1\/Y-/]W0VY^WIUSZ]1C2Y* M[6%01[OT4HHK+G:CL==M3+,58RJR?+Y!BB\LCL6-_(M! MY/GD\N:!#"+6]](^&= A9I./2<0%T7CP M 1^>TPGH_P'-&W8<6 _P!"//'N+A8& J6763/L]<,"--+RDYJQC&OCM^ZK*, M0TF/P3[GLR<*P^/D[[,D\AR%DW$P\&%APQ)2%H7O.?]#:"4B7L+Z,3S8@>^& M"K1,4<-PEG#OC:,,L;_+L \Z:_B/F("2PM1:,,)15AL<*7"LC[178=L-:)<7 M=P'F^QY[@G'SAK&=-.8'"W3%A =1^.3AA+T 7D_"*.:#[H^;AH8ZJ0^_\X[% MM-IA*GH9M>C!J 7*FSI_I9YP3&MB:NX$?>(81E*DDDHNXDFR=?S425)X,R;H MMP(- ]X;,IH/+_'Z2!;HK4"R'U\W=:WQ(2Z. #Z#8^PE0/+^7&IYL>!YS ^" M7,]L-T2?Y@)'@SA$224P9"9DHL\ MYUK6OE!/7L!71J99,J&:%:C%.9;*I ;FKYS91;-$9:]>.%PWSED]P$TA4=!7 M&BWKHX/Z&(;EI%&$+8Z%1R@5\3>HE><>"XHB JJ%Q9ERX68ZZ)\89!I<9>![ M9L./==PE=^E%?Z,:/#@;\0?8.IA V7.@S;?@#/R$,H#OC54@^4MD E2YLR $ MTN>X6$OFNX_SI=UQXOB!.C@PS*A$7'I,%]GA0[XRRKY'#X#MR*N29>_ MRU\@'1@&[XB29\:^,53($?S10Q..@EK \?9 G2?# 9II?'@PX2(QLV'Z%'H: M+?)"3P,D,@KS>!S9:%<9OO!*IJ \LTO=_^3]02P,$% @ 6S".5CYYDL,G M#P 'WD ! !U;F@M,C R,S T,30N:'1M[5U;<]LZDGX_OP++LSMC5YD4 M;[J0MC7E(SN)*HGMLIW*F7V9@DC0PIHB>4#0EO;73P,D95UM1K$NSB@/CBC< M&MT?&MV-)G3RC^$@1(^$I32.3A5#TQ7TC_;)?ZGJGW_*.^C[SY)'U# X@'Z'K,'^HA55;;IQ,F(T?L^1Z9N6C.%S TLJX'MGJ/: M.B:JW<"ZZA@.41NXT? =R[""P#NZ=ZU ][%I8%7O&775[IF!VC)(3_4]8IM$ M#^K-7NO(=_VZXWB63YI68-FMP.Q!K[BN-YJ^3G2_Y8EA^QQF!S.,4I<.3Y4^ MYXE;JST]/6G#'@NUF-W73-VP:C0*:43$E)6BND_HN+ZLFQ)/NX\?:U!0$[,K M*XI"NJQK772=HE0D*K>4BVC[&=NQ&D.BN(>3G,*W1!']Z<*B=1OMPH(F&"_?3(@'"/17B5_ M9?3Q5.G$$0?8JG>C!)IY^=.IPLF0UR2?:^W??OOMA%,>DG86]54A4=TV[)-: M_MU)+>^Y%_NC]HE/'U'*1R$Y57R:)B$>N5$<$1B?#EU1D;#\(_5]$LF/4'X) M2X=1+Q]^R&](<*K0>M#K>4U8"2WBVX[NM?RFWO MQ_(]PW>W8([5S.4AMBE$E5\=LK$VLC!JLGWP127:^IKC_92B3;8J% M-Z"1VB=B=PU=_Q]%5FV?I D&3/58#3K(/^?]S/4F:%9Q M2.\CUP,F$G8LOZ&1X+%K-1(.77+<"TG9HAK&O&\J;[;M^LVYJ4&RLK%&"UW=V=W%[;0FW4%J;R\ZWVZZ=]V+ M6W1V>8XN_NQ\.KO\>($Z5U^_=F]ONU>76YR"66D*WW':!ZSP.#I"YUI' _^I M;CL[3_;??F^9AGF\CO^6SGUZ9P7M>KPK./QP=?,5K='*+IWQW*G)C6PPE5KJ MYUD+&^V1\RIRA$U6?"/T=WTC0+(K,:>3,2:"+C -DI0C\BB@FQ<3_]#=A$:\EC[I1>ZI*BB/-4'W M0^[Z\(TZ@#'[HIGJXY$Z EI5$HWC%$K[+&$T1,BPCV3@ M&WHE7A]<##'H.\&A7$N4G$$X16E"/!&_\A&-$.4I @T)2H(=[A?8ZT(WJ@E] MLS&KEJFU''N5F)5I:E:]\?;A&DNK6ZTW[Q:H;>K..Z+6JE>CMHA9+0N E#$, M,QF**,8\XF8ADJ-C\\I'WXBB[T9>S,"PD0=9MQQ,BTZ<19R-.K$_;7>("V* @[O"P6YQE>7(I34NEH;1M$(ME@LODO"B8U;572(*Y[6W, M])TRO)P9F=D+978@M9'PJ&/>)PS]'[BAJ4]S5QL,,3JIN0YG#L?6C?%?CMF= M>#"@J4B904*IH!R_>[;^)%N[VHUVJZ&+01+&(P#QM)) E[&VB,4O'ZG,&]'; MMYIM'>P^/3\77&PV3Z%BVK:S#7GX_8)=N&)AO;6FCFU'TU=M^W+'C>H=+SZ< M->HOG,[N=^VI7?O,]QE)T^*_+T" 4>[83:7]+:*<^)\(#GD??61QEJ".9-(1 MVHMC4AP=^'C%[N*GL7O14MI?:101'D,_H MMV*T-+"NV#6X[%$A_/E.08>+F<8HX"4G2CR."(NEO' FO+LR$B!!F M!(,(?>*B@S4N0K';G,%04\O.4-I.W9Q==(?K//C[$@/HK@4OID,'A@FT6 W5 ML'3]/9VN5$LPN:R=;>^@I!J)!Q]@5P37+3\ 8G*3A$>/XEVPA*C(D23NJNO_.JL/8/YAPB\(*&$ MT=?;JMI_,7/7J#J_,\J!_R*$E45%:"6=MV9[<1SV,#"3@TC'ZM42*\!IVO;Q M,ANK(KN^@XC$QI4B\Z=0B!#ZP9'?<@T4O 3Y3#(3)1/I3C=92)!MU@NH\NDD M(9$;=& T4>?##0)1:5#Q< _69[#>QB'U@%71_5?0+H+JJDBU]TB=RI$>,Q(- M"D[.P]2P,5A0$TB=RF$;X]36M;SF'JH34+UF1.A4\4Z93-(56QR["@)AG%:# M;'T/V:FD4494;X*CKVI9P_95\Z!W6 W >=T]A)=#N)NF&6$K +FQ!_+/ =DB MJGW@50-R47<30'[3#>G9",KM><+ (T@6)8K+-5W8]S!]=^6$N6V\TFDVG%72 MXRQ+:^GV2IEA+Y?5K;=/NC-MS;16)6C3Q%I-S7"L_[SDN#MQKT&>J>_UD1?B M-/U/3G*Z8U@&3F]'@UX<'OQ0//R78\9ED:XMH4'*K09T[U.?PC?/"OI'LJ\J MO1R[:_Q9G)FR3@\WWP='AMF3*W1L1#65MC#&0 BW//8>CM!_:[J!$LS0(PZS M-6>.[F5717:%#LE5R%AP+?'>QZ>]?+8OGW)ME<9S_G;.K \C]-WTD;WA@$J$ MV?TS9@_YZAO;WZ\?+;]VUBAD9F_+ZNY&OG [".J-D"<#^$#5 ZAY(K-&9Z+K M-$5 (?@L@O![=,_B)]X7WDLB(NXX13X)8 CY.D\>Y]3KI:$^$^3,7X"TT,'? M?C<:S6,9ZRPK4_DB4")?!(I9X0*9/=5J@ M)UZ]$97%_74^9GZ:G_GYR^((U@$>QQ$F]8CV MH]AYVZ4^7DFK1#7V%U7MN]U?5+4?9\,75 FHS/-WGM-K\?O56PJ91M^F/H)_B>J#U&\(.* [ 471P^X5&JU-9X M]:"PJU10J@Q[W$VS 6C@42D#5;S3XS;-TFLK[B-4Q3=;2D3LAE#>A'*$%[W4\OP4-EM:!L*9$!INI'Q=>A'PRC@_!?TPS MJ(+!+A,)R: <" 9+$$<1F&Z>S 8#]@64I1S]EZ$J1'(G'6R<0Y3]%@(4I^Y=1D.4XAM;G MP%&AUD]J>-9+G)6V^!F/O>AV2W37TOVX*=P/7]JXT_[2$L'^,CN!TC9T>ZG> M>P/,;F-*G1BH0=<87(JN.!X'1(H79<\QQ_GU+@>YSR7$#?Y%5]IU2/RTS<3! MXGN*F6TW_K6[[]S>=C]>GMU]NUEPY_UV//[)>Y/S4[:_,LH*MZ:JI[[@>,[/ MP"GV<":.U&0(H;C-%X8!OSD%04!!G-_1V2/@3P?"<18=25595!"!E"R"-K([ MG/%^S&!R?E4?:VDJ\I*HR[82FBOZP^+N87=F/T#+G.2W^ON>+P_=.0?7,#2S M6 _1NXO%>XH0[FUM(8^9YBB3QKZ0N+H?K5["2,)[#9[."FE1:JTJ3LDWJ6K5ODX$+6 6;V:9)_WUM!Y22IEN1]K#Q@KGW MG/MQ;%_.SK=-C1Y!2,K9TO'GGH. 93RGK%PZMS=7^-0Y7\UF9Q\POO]\O4:7 M/.L:8 I="" *H#LN'N@CP7AE21>\?1*TK!0*O" \](JD M",,%B=(81QX!'"V(AV,_!KP@BT4>AWY8%-G',@D++R>!3["7^BTZ:"?FFF=$V1/RICH6C\T2^P$._?E6 MYH[[KK3C0)1)15@&4W+K+SSP_D8-^ZV>5L/ FUZ##28AFY?\T'0_JQ).M>%#(A7\<<[8-RNID"]WCVLNO# M+>[)/>0WQ(S465=/YXU%/4KKC8.*_8!QQQ-F]_UB"EG#;K2M9L]02P,$% M @ 6S".5A%GVIWE!P E3@ !0 !U;F@M,C R,S T,31?9&5F+GAM;-V; M;6_;.!+'W_=3^'QOCS$?)2IHLNBE[2'8[K9HL^CBWAA\&-I"92F0Y";Y]C=2 MXC:)E4W/5.\ O7%DF>+\.;\).4-)+W^YWA2SKU W>56>S-D1G<^@=)7/R]7) M_(^+MT3/?SE]\>+EWPCY\Y\?W\U>5VZ[@;*=G=5@6O"SJ[Q=SSY[:+[,0EUM M9I^K^DO^U1!RVE]T5EW>U/EJW+QK_5Q$"(QTF9$4@-$)H:2C&5 $I,D M/A-,A.#^L3H6@7K#F2'4,D6DY8%H!I9X!Y(##2JUNN^TR,LOQ]V'-0W,<'!E MTW\]F:_;]O)XL;BZNCJZMG5Q5-6K!:=4+':MYW?-K_?:7XF^-*,$X$.[IN_/STQ6QVZSE3N[HJX".$V=WA'Q_/]Y7F M9;OP^69QUV9AB@(5]SVT-Y=P,F_RS64!NW/K&L*3ZG=#[D2I3L[?N]X6T9K6 M**1V6PL$ST+9!?B(&H=ZC]?\K2_B(9AMT8ZH>+_O4?56&Y./Z>"]KD=0VW=$ M-K"Q4(\I]4&_]W3N1#Y6V'6Y+7.YUGU]4?T;=\\^@L[1##KQ'7Z]N[@S$:$$KELH/?CY+/IV!2SQ(9'&,ZJ.5M%YVFG:JB<@]Z++KYK?IFIC 6BO[LTD.^W"TXYV6H MZHVY&PRKZNL" M[2PZ3W8'O4MOL3YC_=;3<:.ZP+9+T"RQUAOBE71$9J"(284BEM),J]0)I>DH MH^BL/53]/4)>U3O]=_\N!_X_=4G 3Z#75B,X[Y8,RI_/JMI#?3*G8T#\ '5> M^3>E?XT9T=)1JZS!!(4QGQ"I6$8TI9)D/+.HB((&,0K-!V8GA/5P=^[S93%\ MWY1MWMY\A%7>M+4IV]_-!I9,V]3(3!.5"4$D>$>LU!D!H97A@ME$Q4TY0U8G M0#?:F?MP>3S<8T]:F6K,\1)0&'LAXR0# M9DF6".NM9S[(N(GY!T1,!OUXKMZ/!!$?"6_S G[?=IY9!$V:X8](P1DRCH;ADD6! J@TO,>,@?V)X:\,,=NX\[B\'= MS32O:C"]#H^3C0Q)0K@3E,BDV\W1J28F$SIED()R613@^]8F@/1@YPULE43M MA74WJ8H/ZZJ$[WF@P*K-$IH:S/\QW<=*(. 12RQGWGL7XF;GQQ8G0#/*B0-$ MHW:_/M=YVT)Y5FTVV_(NQV^6DBIMG,\PQZ,2AR89P:G!$YV"M:"93GD2A770 M[ 38QKMS '#4#MBGJL@=NK%<_89K?YV;8BFTT\RRA!B>=9NMF<2$7F8D98YY M7"%HR.)JXWV;$T ;Z<@!KE'[61]JZ*(,,(WK[Y)TM^OJ]R'@?$)9 $]-0J@1 MF-7I#!<'Z14!K5U*\8/[.+Y/VYX YY$<.\ [:KOKD:SSIME"_4 $-'[CU?3CU/0738Q_GY($(B-KX^@1NB\O+#>/V(F\+ M6 9<25+N,!-,9+?YBK(L,$TLYPEFB51F)H[X8XL3(!SEQ &B4=M;%[7I'L'[ M=+.Q5;&4UC!A%&8)66HZ)5B'!RY1CL.?M$AD8%$X'YB; ,O#W3< ,FH':Q=5 M;Z[=VI0KZ&][9A;+,H&)@3<:4% W5ZA$$V\=SZR2G-JXVFC(Z@2P1CMS@.X( M6U5O-E"O,-S^55=7[1J7B4M3WBRU5IC"TT"DP#E$ H[/0NB?7@C@O,!*?8R; MQX/&)\!Z+-<.((_:KKK5=8;#K4UQCNO_]:]PL^3!6*><)BS1N/H+FZ(BK@B3 MPCCF4J]#7%D\:'8RF&/<.?!<2-1.UBLE<&G?G\(&Y"0 ]W'T#(*,VL :&=V$L)G882DQYCRJ4\$2&E!$L MV 1QVAO%,\=L&.<)O<>61\1[[XG[_^&C>5&N''HZ;W;[+/6Q*ZH&_,F\K;?P M_615MG#=OBGZDNMDWL"J.Q@Y)G:G7EWG#283+I,:IQOI-"XO%.<91AGFG_JC9%G&1^.9 !UA#]_+F$=F,P2S4@P JN#[EE3#6!(1BW/9&*4 MA#]_S6@]U="AEWOSV,)\YOU2VB-/D[1E\Y9XY*A&I MC)/KMV=_7'T"P=EO[UZ\>/,W /[ZU[=+YT,J[N8JR9WS3+%<2><^SF^YR-O];?8Z\CS", \!=ID"F# 7 MA#!4@#!"9.A!+XK$R^O77N1*AB #+H<^P!Q%(("* RD41LJ-?,J#,N@L3GZ^ M+O[#V4(Y.KED4?[X]NPFSV]?3R;W]_>O'G@V>Y5FUQ/DNMYD/?IL-?QA;_R] M5XZ&81A.RM]NAB[BNH$Z+)S\]?OE=W&CY@S$R2)GB2@F6,2O%^6;EZE@>>GY M05U.XXCB)[ >!HJW $3 @Z\>%O+LW0O'6=J1I3/U345.\>\?WRX:IPPGQ8A) MHJZ+;_:KRN)4?L]9EE\RKF9:?1DM?[Q5;\\6\?QVIM;OW60JJ@\[R[)*U$)E M6*B$I%#Y]Z;))CWD'TEOOJ_U".+*=#\?2V.;IY^/)O=*KP_J](*WINDM>7E M?4SD4,?N9JK>TD^O^%B'19JSV0"'Q=,T6Y)GQ1N7^M5JFB)0RV):SK-:NK>D MJH=<)5(M5\M*:">6;\_TJZE4\71]UMM\U1^TL*DBS*>00Z#/00A@)3 (>.@! M(3F' 44B"O TWQS44Y6 /[ZOYR\G.3##68?<\@9&,[5([S+Q=':;S^I.6?IL M59S?@DG"YFIQRU8?T#*+0F"I_-WFY+]4Z6B93J'SS>0I)1LC9Z>W9S8R9U)1 MT3(KRH$TV\T^%8>S?^)KH867J2^4>'6=_IKHSTZ*LJMX 8H7)5;-$2=[7][[ M;*V39>* SZL1$Y'J6NE];I:<^<-),JT_5K30J5X^]K MIL[3N8XH5!'VJH _^Q)%*ILBP5 0!A' -*"ZQ%0!8,JE@%.?4"8()428TMP\ MS=B0UDJ!V)+J++4ZI5ASKEM\/0SW<=PZ,>%V1G7"_+ /5JRWA!T,^,.I;5-O M,+H[^M_362SB7%_8_J[7D"QFLRF+. \CJ4_;7N@"'&!]51G!$'@>\A'D @D8 MF"*_'WYLJ#\I=-82S0&O<>\PV/T\.3'07>SHA'%SUE;XUH0;#-OF5+9Q;1G5 M'=/S.']\GREVGDHU]0/NXCTP!W0X\-C0+ M;4XASBG4F5-9,>LPC[86G)A$P^P[05B7JA5^E4"#@5! MI-1?Y^)KNM 7VO^-;\NCB3!( D^?&R54L.BXAB#T& >!0C1 B"KL&Y?#S=., M#<2E4FO$U-I:U0GCPTY80=T2=C#$#Z>V#;S! M:%O\SW6)G;'9A2ZR'_ZC'J>(HL!U)0&8"0EP!#7T/D6 <\&9!Q5EU.]&_LX, M(X5^I=(I93I:9U?:=XTT!;V'/<,P;NZ,!=P-V??@>C?BP$@W)+1/<]/ [B"O MVV0?TCF+DRD*"$2"". %# 'L(P$X]2(0\D I[G-&S,BDO82%?. $N"0>!&%' L@E!@CP34>).H88ZQ0;E;&9;7=VGF%%HM M*^@M0SN6SW8V#5P[&SED7SCO>]"_:MZ*^3PE\WY2C?5RS5"+_K$2=YD.]/%! MW.CO4GW6W^\4"C?PB2< Y3X&&!$(0B60ODKF8<0AI9A XPYRS01C0WNMT5F+ M= J5'=K(=28:-))[6G/J5G(W5[IUDUM2M^LGUP4B/A5 MG,_45%'A^8'T@$_*K1^/ WTVCH 7,0&IBZ# O"NXZ^!C@[84Y:21 ]$_^#^= MM=SNU&[<,R?6QI,3T]K5#BM<=_/NA>HFV."8[J91A^C>F.YX_JGCY"HI-GWO MDGAY9^QBJF2D*%,AB)#0)]>($J!_4H!#(3U"?#= RI31VAG&!NI*I%-5:UMSHF)[>A+)V!;<[>BMC[B8.BV)K3-;_M ^R;411*EV;P,=QDGZB)7 M\\64*03#B%(@])E77P8S D(6A< 73'",* FI<:'<-M'8D-[T9K;$.C\*N4ZI MUZ)A5>NO>?NJKVM#-;,Z&V;5W&ISHU>KJS;PX(VOMO3JVF"MX[LO"<53+K.O M-VFB/M_-NBBD&-LO*N\&WQLZ)?ZG%*@ MLU1HSOJ><8?Y[F/'B9GNX$0GB)M2M@)W+]A@L#:EL0UHXYCN4%YEK'B\[_OC MG*?ZD(I\3!&5P/>\$&!%O.5N;T1P@%'@!J%DID16(H\-QY4X9ZG.',6J78]9OEW K V5ROZJI$&0Z\V@6WNZ@?8;@]=)"+-;M.L/,%^SUFNSM.[ M),\>RQN#7"4"5S()1$19\1@"!@'!%$#"1,"X4)AYW;:*6N<;&Z"K39&*YI=. MJ;K8&UDIM[H/J]UWTQVEH[DYS.Y2+R,M-IN,[.FQ\=0>?^!-**-D]S>DS#[6 M<_>YC/LE^YJEOV*=SC0BOE0T),#WJ0]P""/ !8<@DA#Z@8 8$>,^6MM$(UU0 M-KNL&P+6@BTWHW?]-5T_^KLVS,)A89C]WG2#&_TWJ'<#/\\N=4-ZC5O53>-[ M/^IXL5CYRJ[U%?2_L_0^O]''["U+'J3+E@OHQ4J(O0T -8ZG(T0$4Y"@65"A%( M_,Z/*C3,-;;%H&ZG\^73']C[46CNMSU<=BWZ4@D"X$V)4HH@'V26C,6B7RV&#;B',*=>:T M5>TZC)NU"2?FS3#_3L#5YFI%7#728,C5)K#-7/V HY3$5XS/U!1&5!$A78!X M\==NI(\!D\@#U,-"*HQ#9K[_VS3)V%"LO]VOE-JO]EU::E7T=C;J&:K=@Q[U M+7(K)ARKNET&?%P,YW/^X99]K3LK-CF$:6B1,6S:O]E'MTK+:" M#=RFVD]COS=5,\86RBOV<"$U[7&T>O!A=: Q3R(E0Q<$$=67FT+I5Y@HX'L^ M)YY'N2:X&Z$-,XT45ZW6JMHUS$+0W2G[FZ;JG.A_QU0EZO/<+E67 M6..]4K6#;<'_IJ[C8LL[R0@P00($$$G@^LJE4 2Z8C?> MEZJ;8*2X/XGL^(<]:DTTY=O>FF'0-G7% NCZU'NPO!-P8(SKT]DGN&%<$[S; MCFO66SNE__]SG(O'Z MEYM-L?@"=9-7Y>$>VZ=["RA]%?)R=;CW^\4[HO=^.7KUZO4_"/GCWQ_.%F\J M?[6!LEV!!;!<7E]?[]^XNMBOZM62 M4RJ6#Z/W[H??/!E_+?K1S!BS[+_].K3)GQN(EV7+/WX]^^C7L+$D+YO6EKXS MT.0'37_PK/*V[37_2[\6/QW1?2(/PTAWB#!.!-N_:<+>T:O%XDZ.NBK@ \1% M]_?W#Z>/3%Z5.:[B&FS1KE=U=76Y[ZO-LANY/*F0"_2YOT9[>PF'>TV^N2S@ MX=BZAGBX=U6N2;>V5#+9&?[GW7G+;_8O:V@0F7Z^9WC@_O3.R A?X*:%,L#= M1!],%95_-*CH9*Z^GEE8!T5_- N09_U5CUW3UM:W69!,AR2FA*52$,F](59I M3WBB4NDA\3[1CZ?>^=Z@\_VJ-.#W5]67)5YXV>G1O>F%Z45Y8NY.H.W\?O@1 MGI:QJC>]KA?6%9 YX$R%D!"M1" RIHQHHP7Q.EC%C6^6#EW? M6Z "$>H:PMG=ROUTHOTL6]Q_H1\Y,14/AXYO\B8SSANI74JDUQ'W6ZZ(!A\( M4+!&Q!0]-E/#\;T#+\?(-*O[Y[AL+?6.4/.FVMB\S'1DTB2:D6@%QF-I-'H. MEACJN,'PK)2?9@>YL[=33&R_A,^@L86>.T+"=XI@M(;3%C9-)CA(YZPF5%%, MUBP%@A\%$5R'D :!N9F<>O/X:GT0)7RN.\=V(N\(+!")4%)3Z0! M16PJ%'&4&JU2+Y2FD\#16=NI+6/+M7L&B+\MY(X < YU7H6W97B#Y6#FJ5/. M8G7&&/XVI&*&:$HE,=PXG $%#=.$CT=F=VI_F Z)[:5]83;>EFW>WGZ 5=ZE MY67[F]U QC"8VB[^*2,P-8?@B9/:$!!:62Z82]2X"/*0&_76TQ$HZ,U;&2KQ+G)S@V_?U175=9L9(YD&DR':" MQ3]7@NC@4L+!HPM*,)5,$6^>&![$B)XG(UO*NTN$]#G5^_J\KK[DI8=,"4R^ M=4()UNU(>N#(O/9 =%?!6)6#.JZ:UQ?_RRSX# MQUDH*@4GRG4%?F",V$1!=S\\P2)?60RCT^'RR/:PGAJ=)RW;J_S"K'1;XG$- MMO<[X*XH8Y(0[@4E,NE:@SK5Q!JA4P8I*#_N[MWWUH;Q,)\FZ]9*OC !W5,B MQ?FZ*N%;DBVP%'>$IA8+,ZS#L$2+^(XECK,0@H_C0LJ/%H>1,)_>ZBA%7YB& M3W7>ME">5)O-57E??#69I$I;'PPFT%2B$I(1W,("T2DX!YKIE">CD'C6[# N MYM-9':_M"\/QL2IRG[=YN?H5DZ,ZMT4FM-?,L818;KH[!D9BI24-29EG :,@ MC69<\^.IS6%8S*=S.E+5%V;BO(8.:, 32 M1T^LCYP(R5VBN B6PY3$//%@&#?S::=.JOA+1Q_P5QA!;QEW%WE;0!8Q6*;< M8Y*=R.X. L[" =/$<9Y@ DZEL>-H^='B,#KFTT =I>@+TW!1V^X?"#[>;EQ5 M9-)9)JS"),JDMG,<,,/F$KWW^)46B8QL% J/S WC8#Y-TNVUW)$MX>V-7]MR M!?VS"L9AI2TP;PI6 _K?;6DJT20XSXU3DE,WKGY]SNHP).;3"QVM[$[T0-]N MH%XAV?^IJ^MVC9'PTI:WF=8**RL:B12XU4E .1S$_E&G"#X(&9,IGOYXUOBP MQ\CFU@4=K_-.X'*"ZM2V.,7TZ.:_<)OQ:)U77A.6:$R.A$MQ EP1)H7US*=! MQW%MCV?-#D-D/HW1\=J^,!S'*$GH9'E7V%6F TNB]SAY+AQ!130Q"22D:^)@ MGB2]3\?=OG]D;A@,\^F-;J_E9!"\7C[1$N?U^>C5_1?=2_?/CD>O_@]02P$" M% ,4 " !;,(Y6X$S/,@XS ST ( %0 @ $ 83(P M,C-Q,65X:&EB:70Y.3$N:'1M4$L! A0#% @ 6S".5CYYDL,G#P 'WD M ! ( !03, '5N:"TR,#(S,#0Q-"YH=&U02P$"% ,4 M" !;,(Y61F)]%W<" "#" $ @ &60@ =6YH+3(P,C,P M-#$T+GAS9%!+ 0(4 Q0 ( %LPCE819]J=Y0< )4X 4 M " 3M% !U;F@M,C R,S T,31?9&5F+GAM;%!+ 0(4 Q0 ( %LPCE9" M,4&\K L ,IL 4 " 5)- !U;F@M,C R,S T,31?;&%B M+GAM;%!+ 0(4 Q0 ( %LPCE8JQ^.+=0< +HZ 4 " M 3!9 !U;F@M,C R,S T,31?<')E+GAM;%!+!08 !@ & (4! #78 " ! end